BRPI0907122A2 - Piridoindóis (1-azinona) substituídos - Google Patents

Piridoindóis (1-azinona) substituídos

Info

Publication number
BRPI0907122A2
BRPI0907122A2 BRPI0907122-9A BRPI0907122A BRPI0907122A2 BR PI0907122 A2 BRPI0907122 A2 BR PI0907122A2 BR PI0907122 A BRPI0907122 A BR PI0907122A BR PI0907122 A2 BRPI0907122 A2 BR PI0907122A2
Authority
BR
Brazil
Prior art keywords
azinone
pyridoindoles
substituted
substituted pyridoindoles
Prior art date
Application number
BRPI0907122-9A
Other languages
English (en)
Inventor
Peter Guzzo
Matthew David Surman
Alan John Henderson
May Xiaowu Jiang
Mark Hadden
James Grabowski
Original Assignee
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Res Inc filed Critical Albany Molecular Res Inc
Publication of BRPI0907122A2 publication Critical patent/BRPI0907122A2/pt
Publication of BRPI0907122B1 publication Critical patent/BRPI0907122B1/pt
Publication of BRPI0907122B8 publication Critical patent/BRPI0907122B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0907122A 2008-01-11 2009-01-09 compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos BRPI0907122B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2053008P 2008-01-11 2008-01-11
US61/020,530 2008-01-11
US4867708P 2008-04-29 2008-04-29
US61/048,677 2008-04-29
PCT/US2009/030646 WO2009089482A1 (en) 2008-01-11 2009-01-09 (1-azinone) -substituted pyridoindoles as mch antagonists

Publications (3)

Publication Number Publication Date
BRPI0907122A2 true BRPI0907122A2 (pt) 2015-07-14
BRPI0907122B1 BRPI0907122B1 (pt) 2019-04-16
BRPI0907122B8 BRPI0907122B8 (pt) 2021-05-25

Family

ID=40429805

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907122A BRPI0907122B8 (pt) 2008-01-11 2009-01-09 compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos

Country Status (13)

Country Link
US (4) US8716308B2 (pt)
EP (2) EP2240481A1 (pt)
JP (2) JP5501251B2 (pt)
KR (1) KR101614723B1 (pt)
CN (1) CN101945872B (pt)
AU (1) AU2009204048B2 (pt)
BR (1) BRPI0907122B8 (pt)
CA (1) CA2727055C (pt)
ES (1) ES2523580T3 (pt)
IL (1) IL206594A (pt)
MX (1) MX2010007430A (pt)
NZ (1) NZ586120A (pt)
WO (1) WO2009089482A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716308B2 (en) * 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9187455B2 (en) * 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) * 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
JP6129850B2 (ja) * 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体
HU230880B1 (hu) * 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
CN112739689B (zh) 2018-12-07 2022-06-03 优迈特株式会社 含氟嘧啶化合物及其制造方法
EP3937932B1 (en) 2019-03-13 2025-01-08 The Rockefeller University Inhibitors of cgas for treating autoinflammatory diseases and cancer metastasis
AU2021206286A1 (en) * 2020-01-10 2024-08-08 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
EP4155299A4 (en) 2020-05-19 2024-07-10 Unimatec Co., Ltd. Fluoropyrimidine compound and fluoropyrimidinone compound
MX2023009059A (es) * 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
CN118251386A (zh) 2021-11-12 2024-06-25 优迈特株式会社 含氟嘧啶化合物、有害菌类防除剂和含氟嘧啶化合物的制造方法
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3514462A (en) * 1966-10-21 1970-05-26 Upjohn Co 1 and 2 ethoxy 3,4,5,10 - tetrahydroazepino(3,4-b) and (2,3-b)indoles and corresponding amino derivatives thereof
CH649553A5 (de) 1982-05-06 1985-05-31 Sandoz Ag Azepinoindole und verfahren zu deren herstellung.
WO1988001165A1 (en) 1986-08-11 1988-02-25 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
IT1223343B (it) 1987-11-03 1990-09-19 Also Lab Sas Formulazioni farmaceutiche per somministrazione transdermica
US4985422A (en) * 1988-04-27 1991-01-15 Glaxo Group Limited Lactam derivatives
HU207078B (en) * 1988-08-02 1993-03-01 Glaxo Group Ltd Process for producing lactam derivatives and pharmaceutical compositions comprising such compounds
US5223625A (en) * 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
AU5194990A (en) 1989-02-23 1990-09-26 Rorer International (Holdings), Inc. Therapeutic aerosol formulations
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
US5169852A (en) 1989-06-08 1992-12-08 Neurex Corporation Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives
US4978669A (en) 1989-06-08 1990-12-18 Neurex Corporation Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
CA2036337C (fr) * 1990-02-15 2003-04-15 Francois Clemence Derives de la 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5162336A (en) 1990-06-21 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists
US5187180A (en) * 1990-07-26 1993-02-16 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
JP2951434B2 (ja) 1991-04-18 1999-09-20 三菱製紙株式会社 電子写真感光体
DE4130933A1 (de) * 1991-09-13 1993-03-18 Schering Ag Neue (beta)-carbolinderivate, deren herstellung und verwendung in arzneimitteln
DE4240672A1 (de) * 1992-11-24 1994-05-26 Schering Ag Neues Verfahren zur Herstellung von beta-Carbolinen
US5767131A (en) * 1993-04-05 1998-06-16 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
IL109220A0 (en) 1993-04-05 1994-07-31 Synaptic Pharma Corp Dihydropyridines and new uses thereof
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
GB9418326D0 (en) * 1994-09-12 1994-11-02 Lilly Industries Ltd Pharmaceutical compounds
WO1996003400A1 (en) * 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
DE4436190A1 (de) 1994-10-10 1996-04-11 Gerhard Prof Dr Bringmann Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
WO1996012721A1 (en) 1994-10-20 1996-05-02 American Home Products Corporation Indole derivatives useful as serotonergic agents
US5466688A (en) 1994-10-20 1995-11-14 American Home Products Corporation Pyrido[3,4-B]indole derivatives as serotonergic agents
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
EP0801557B1 (en) 1995-10-12 2003-07-02 Supergen, Inc. Liposome formulations of 5beta steroids
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
CA2246756A1 (en) 1996-02-28 1997-09-04 Merck & Co., Inc. Fibrinogen receptor antagonists
US5932582A (en) * 1996-06-28 1999-08-03 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2257950A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
JP2000514061A (ja) 1996-06-28 2000-10-24 メルク エンド カンパニー インコーポレーテッド フィブリノーゲン受容体拮抗物質
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US6713645B1 (en) * 1996-10-30 2004-03-30 Eli Lilly And Company Substituted tricyclics
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
PT1064284E (pt) 1998-03-17 2002-09-30 Besins Int Lab Derivados hipnoticos de beta-carbolina processo para a sua preparacao e seu uso cmo produtos medicinais
ID23219A (id) 1998-04-17 2000-03-30 Lilly Co Eli Trisiklik tersubstitusi
BR9911031A (pt) 1998-05-20 2002-01-29 Liposome Co Inc Novas formulações em partìculas
CA2335115C (en) * 1998-06-16 2009-01-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fused azepinone cyclin dependent kinase inhibitors
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
AUPP494798A0 (en) 1998-07-29 1998-08-20 Pacific Biolink Pty Limited Protective protein formulation
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
BR9916821A (pt) * 1998-12-14 2001-10-16 Nuclear Receptor Res Ltd Ligantes de receptor nuclear
EP1338272A1 (en) 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
BR0007974A (pt) 1999-02-03 2001-10-30 Powderject Res Ltd Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
EP1158961A1 (en) 1999-03-08 2001-12-05 PowderJect Research Limited Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6407092B1 (en) * 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
JP2003501404A (ja) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法
MXPA01012914A (es) 1999-06-15 2004-04-21 Bristol Myers Squibb Co Gama-carbolinas fundidas de heterociclo substituido.
US6713471B1 (en) * 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
CA2382821A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
MXPA02007052A (es) 2000-01-20 2002-12-13 Basilea Pharmaceutica Ag Composiciones que se administran nasalmente y que contienen peptidos ciclicos.
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
US6890933B1 (en) * 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
CO5261594A1 (es) 2000-03-02 2003-03-31 Smithkline Beecham Corp Inhibidores de myt1 cinasa
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
KR100826817B1 (ko) 2000-03-15 2008-05-02 사노피-아벤티스 도이칠란트 게엠베하 치환된 베타-카볼린
CA2406206C (en) 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
US6469020B2 (en) 2000-05-15 2002-10-22 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
EP1289989A2 (en) 2000-06-07 2003-03-12 Lilly Icos LLC Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
IL153115A0 (en) 2000-06-16 2003-06-24 Curis Inc Angiogenesis-modulating compositions and uses
AU2001269781A1 (en) 2000-07-06 2002-01-21 Pharmacia And Upjohn Company Substituted 2,3,7,8,9,10,11,12-octahydroazepino(4,5-b)pyrano(3,2-e) indoles
AR035493A1 (es) 2000-09-20 2004-06-02 Upjohn Co Derivados de azepino (4,5b) indolina sustituidos, composicion farmaceutica y el uso de dichos derivados para preparar un medicamento
AU2002213419A1 (en) * 2000-10-02 2002-04-15 Lilly Icos Llc Condensed pyridoindole derivatives
EP1335923B1 (en) 2000-10-03 2006-07-12 Lilly Icos LLC Condensed pyridoindole derivatives
FI20002768L (fi) 2000-12-18 2002-06-19 Licentia Oy Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus
EP1345898A2 (en) * 2000-12-18 2003-09-24 Eli Lilly And Company Teracyclic carbazole derivates and their use as spla2 inhibitors
US6849619B2 (en) * 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
MXPA03005438A (es) 2000-12-20 2004-05-05 Bristol Myers Squibb Co Pirioindoles substituidos como agonistas y antagonistas de serotonina.
HUP0303316A2 (hu) 2000-12-20 2004-01-28 Bristol-Myers Squibb Pharma Company Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények
JP4220779B2 (ja) 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
MXPA03007142A (es) * 2001-02-12 2004-05-24 Lilly Icos Llc Derivados de carbolina.
GB0107106D0 (en) 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
CA2441792C (en) 2001-04-25 2010-08-03 Lilly Icos Llc Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2002098875A1 (en) 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
US20030019437A1 (en) 2001-07-26 2003-01-30 John Fore Ungulate game animal feed system and method
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
JP2005526691A (ja) 2001-08-08 2005-09-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療剤１Ｈ−ピリド［４，３−ｂ］インドール
ES2307779T3 (es) 2001-08-16 2008-12-01 Baxter International Inc. Formulaciones de microparticulas a base de propelentes.
ATE469648T1 (de) * 2001-09-05 2010-06-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
AU2003230689B2 (en) 2002-03-20 2006-06-29 Alkermes, Inc. Inhalable sustained therapeutic formulations
CA2484724C (en) 2002-05-07 2007-01-16 Ferring B.V. Pharmaceutical formulations
US6951881B2 (en) * 2002-05-10 2005-10-04 Wyeth (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
US6906095B2 (en) * 2002-05-10 2005-06-14 Wyeth Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2004030629A2 (en) 2002-10-01 2004-04-15 Predix Pharmaceuticals Novel neurokinin antagonists and methods of use thereof
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0305553D0 (en) 2003-03-11 2003-04-16 Glaxo Group Ltd Compounds
EP1462103A1 (en) 2003-03-25 2004-09-29 Faust Pharmaceuticals NO donors, combination products and uses as modulators of neurotransmitter release
US7385055B2 (en) * 2003-05-19 2008-06-10 Board Of Trustees Of Michigan State University Preparation of hymenialdisine derivatives and use thereof
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
CN1798556A (zh) 2003-06-06 2006-07-05 麦克公司 作为治疗或者预防糖尿病的二肽基肽酶抑制剂的稠合吲哚
WO2004113336A1 (en) 2003-06-16 2004-12-29 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
JP4377881B2 (ja) 2003-08-01 2009-12-02 日本曹達株式会社 フェニルアゾール化合物、製造法および抗酸化薬
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
JP2007518822A (ja) * 2004-01-23 2007-07-12 カイロン コーポレイション 抗癌剤としてのテトラヒドロカルボリン化合物
EP1715855A4 (en) * 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
JP4734119B2 (ja) * 2004-02-12 2011-07-27 田辺三菱製薬株式会社 インダゾール化合物及びその医薬用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US20050187387A1 (en) 2004-02-25 2005-08-25 Lynch John K. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
US7705017B2 (en) * 2004-05-03 2010-04-27 En Vivo Pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases
AU2005239811B2 (en) 2004-05-12 2010-06-17 Bayer Cropscience Ag Plant growth regulation
JP2008501628A (ja) 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
WO2006015035A1 (en) 2004-08-02 2006-02-09 Smithkline Beecham Corporation Useful compounds for hpv infection
DE102004039382A1 (de) 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2371811B1 (en) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
EA014956B1 (ru) 2004-12-17 2011-04-29 ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений
US20060167259A1 (en) * 2005-01-21 2006-07-27 Cephalon, Inc. Direct racemization of indole derivatives
WO2006081072A1 (en) * 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
WO2006089874A1 (en) 2005-02-22 2006-08-31 Gpc Biotech Ag Benzo[2,3]azepino[4,5-b]indol-6-ones
DE102005016460A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
EP1879591B8 (en) 2005-05-04 2012-04-04 DeveloGen Aktiengesellschaft Use of azapaullones for preventing and treating pancreatic autoimmune disorders
EP1885454A2 (en) * 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
WO2006122931A1 (en) * 2005-05-20 2006-11-23 Biovitrum Ab (Publ) Beta-carboline derivatives and theri use as ghsr modulators
JP2008542301A (ja) * 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
RU2008105071A (ru) 2005-07-14 2009-08-20 Айрм Ллк (Bm) Соединения и композиции в качестве миметиков tro
AU2006275694A1 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
CA2619276A1 (en) * 2005-08-12 2007-02-22 Genentech, Inc. Pentacyclic kinase inhibitors
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EP1757607A1 (en) 2005-08-24 2007-02-28 Molisa GmbH N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
JP2009508872A (ja) 2005-09-16 2009-03-05 セレネックス， インコーポレイテッド カルバゾール誘導体
MX2008004024A (es) * 2005-09-23 2009-02-27 Schering Corp Antagonistas de receptor de glutamato metabotropico-1 tetraciclicos fusionados como agentes terapeuticos.
WO2007062175A2 (en) 2005-11-21 2007-05-31 Amgen Inc. Spiro-substituted tricyclic heterocycles cxcr3 antagonists
CA2633243C (en) 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US20090131407A1 (en) 2005-12-16 2009-05-21 Brian Safina Tetracyclic kinase inhibitors
JP5193878B2 (ja) * 2005-12-21 2013-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｃｈ−１が媒介する疾患における使用のための新規な置換ピラジノン誘導体
EP2010521A1 (en) 2006-04-19 2009-01-07 Novartis Ag Indazole compounds and methods for inhibition of cdc7
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US20080124319A1 (en) * 2006-05-16 2008-05-29 Charalabos Pothoulakis Methods for treating inflammation by disrupting MCH-mediated signaling
US7872017B2 (en) * 2006-05-19 2011-01-18 Abbott Laboratories Fused bicycloheterocycle substituted azabicyclic alkane derivatives
UY30378A1 (es) 2006-06-02 2008-01-02 Janssen Pharmaceutica Nv Nuevos derivados de piridinona n-aril y n-heteroaril sustituidos para usar en enfermedades mediadas por mch-1
WO2007142217A1 (ja) * 2006-06-07 2007-12-13 Banyu Pharmaceutical Co., Ltd. １－フェニルピリドン誘導体
CN101074207B (zh) 2006-06-08 2014-03-26 中国科学院成都有机化学有限公司 一类水溶性的手性二胺衍生物及其应用和制备
CN101108859A (zh) 2006-07-17 2008-01-23 上海恒瑞医药有限公司 长春碱类化合物、其制备方法及其在医药上的用途
RU2317989C1 (ru) 2006-08-24 2008-02-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ АЗЕПИНО[4,3-b]ИНДОЛЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
BRPI0716579A2 (pt) * 2006-08-25 2013-10-08 Boehringer Ingelheim Int Derivados de piridona com atividade antagonista ao mch e medicamentos que compreendem estes compostos
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
WO2008046155A1 (en) 2006-10-20 2008-04-24 Dia-B Tech Limited Methods for regulating glucose homeostasis and agents therefor
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
EP2102208B1 (en) * 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
WO2008081282A2 (en) 2006-12-20 2008-07-10 Glenmark Pharmaceuticals S.A. Process for the synthesis of n9-(3,5-dichloro-4-pyridyl)-6- difluoromethoxybenzo(4,5)furo(3,2-c)pyridine-9-carboxamide and salts thereof
BRPI0806537A2 (pt) 2007-01-10 2014-04-22 Albany Molecular Res Inc Indazóis substituídos por 5-piridinona
AU2008204915B2 (en) 2007-01-10 2013-02-07 Albany Molecular Research, Inc. 5-furopyridinone substituted indazoles
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
DE102007009235A1 (de) 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009319A1 (de) 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2008106594A2 (en) 2007-02-28 2008-09-04 The Arizona Board Of Regents, On Behalf Of The University Of Arizona Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis
CN101796051B (zh) 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
US20090214529A9 (en) 2007-05-22 2009-08-27 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
WO2009003003A2 (en) 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
AU2008269513B2 (en) * 2007-06-26 2011-06-16 Astrazeneca Ab 1-cyanocyclopropyl-derivatives as cathepsin K inhibitors
ATE544759T1 (de) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
CA2597193A1 (en) 2007-08-13 2009-02-13 De Montfort University Compounds and uses
WO2009022104A1 (en) 2007-08-13 2009-02-19 De Montfort University Fascaplysin derivatives and their use in the treatment of cancer
TW200918536A (en) 2007-08-29 2009-05-01 Schering Corp Tetracyclic indole derivatives and methods of use thereof
US11202775B2 (en) * 2007-09-25 2021-12-21 Minerva Biotechnologies Corporation Methods for treatment of cancer
US8716308B2 (en) * 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9625475B2 (en) * 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof

Also Published As

Publication number Publication date
JP2014129417A (ja) 2014-07-10
EP2240481A1 (en) 2010-10-20
JP5501251B2 (ja) 2014-05-21
KR101614723B1 (ko) 2016-04-22
IL206594A (en) 2015-05-31
NZ586120A (en) 2012-07-27
JP2011509937A (ja) 2011-03-31
US9650378B2 (en) 2017-05-16
US20170204095A1 (en) 2017-07-20
BRPI0907122B1 (pt) 2019-04-16
CA2727055A1 (en) 2009-07-16
CA2727055C (en) 2016-12-20
EP2476680A1 (en) 2012-07-18
MX2010007430A (es) 2010-12-21
US20160159798A1 (en) 2016-06-09
AU2009204048A1 (en) 2009-07-16
AU2009204048B2 (en) 2013-08-01
EP2476680B1 (en) 2014-08-27
WO2009089482A1 (en) 2009-07-16
IL206594A0 (en) 2010-12-30
US20100331339A9 (en) 2010-12-30
US20140206696A1 (en) 2014-07-24
CN101945872B (zh) 2014-07-23
US20090275590A1 (en) 2009-11-05
US9296743B2 (en) 2016-03-29
ES2523580T3 (es) 2014-11-27
BRPI0907122B8 (pt) 2021-05-25
US8716308B2 (en) 2014-05-06
CN101945872A (zh) 2011-01-12
KR20100124251A (ko) 2010-11-26

Similar Documents

Publication Publication Date Title
NO2018009I1 (no) Dupilumab
FIC20170031I1 (fi) alirokumabi
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
DK2370462T3 (da) Glucagon-analoger
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
BRPI0907376A2 (pt) Fotobiorretador
DK3444343T3 (da) Polypeptider
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
DK2342454T3 (da) Vindkraftanlæg
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
DK2379557T3 (da) Aminopyrazol-forbindelse
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
BRPI0907522A2 (pt) biarlamidas
DE112009000183A5 (de) Sicherheitsvorreiber
EP2280264A4 (en) STANDARD AGENTS
BRPI0909634A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
DK2344933T3 (da) Uretui

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF